Compare Eaton Corporation plc (ETN) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eaton Corporation plc vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? Eaton Corporation plc trades at $405.64 (market cap $166.36B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M). The key difference: Eaton Corporation plc is far larger — about 171× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Eaton Corporation plc pays a 1.03% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eaton Corporation plc for 32 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| ETN | MRVI | |
|---|---|---|
Market Cap | $166.36B | $972.90M |
Volume | 1,762,788 | 4,325,710 |
Sector | Industrials | Health |
52-Week High | $459.96 | $9.00 |
52-Week Low | $315.82 | $2.83 |
Typical Hold Time | 32 Days | 0 Days |
Enterprise Value | $186.99B | $1.08B |
Dividend Yield | 1.03% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eaton (ETN) trades at $428.31, up 0.38% on the day, with a neutral technical signal and bullish moving averages. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Strong profitability is evident with a net income margin of 12.75% and ROE of 19.71%. Recent news highlights growth from data center and aerospace demand, supported by strategic acquisitions like COL Group (Business Wire, 2026-09-25).
The outlook remains positive given analyst consensus with a $502.38 price target and 70% buy ratings. Key opportunities include exposure to AI-driven data center expansion and grid modernization. Risks involve execution of acquisitions, competitive pressures, and macroeconomic sensitivity. Valuation multiples like a P/E of 43.62 suggest premium pricing relative to earnings growth.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eaton Corporation plc
Eaton is a global power management company providing energy-efficient solutions for electrical, aerospace, and industrial sectors. It focuses on improving sustainability through intelligent power technology.
Read more on ETN →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
